Abbott Laboratories (NYSE:ABT) Now Covered by Robert W. Baird

Equities research analysts at Robert W. Baird started coverage on shares of Abbott Laboratories (NYSE:ABT) in a report issued on Wednesday,Benzinga reports. The firm set an “outperform” rating and a $121.00 price target on the healthcare product maker’s stock. Robert W. Baird’s price target indicates a potential upside of 33.44% from the stock’s current price.

ABT has been the subject of a number of other research reports. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Daiwa Securities Group cut shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research note on Wednesday, April 22nd. Evercore lowered their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Benchmark reduced their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Barclays reduced their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $118.42.

Abbott Laboratories Price Performance

ABT stock opened at $90.68 on Wednesday. The stock’s 50 day moving average price is $88.91 and its 200 day moving average price is $104.84. The firm has a market cap of $157.95 billion, a P/E ratio of 25.40, a PEG ratio of 1.60 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the business posted $1.09 earnings per share. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Abbott Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at about $25,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in Abbott Laboratories during the fourth quarter valued at $26,000. Finally, Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $26,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.